Rathbones Group PLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 917,269 shares of the medical research company's stock after selling 88,191 shares during the period. Thermo Fisher Scientific comprises approximately 2.2% of Rathbones Group PLC's investment portfolio, making the stock its 9th largest position. Rathbones Group PLC owned 0.25% of Thermo Fisher Scientific worth $619,202,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in TMO. BlackRock Inc. acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $15,501,867,000. Corient Private Wealth LP acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $382,547,000. Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $1,974,561,000. Bank of America Corp DE bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $1,952,930,000. Finally, Legal & General Group Plc bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $1,122,351,000. 89.23% of the stock is owned by institutional investors.
Key Headlines Impacting Thermo Fisher Scientific
These are some of the TMO headlines that stood out recently:
Thermo Fisher Scientific Stock Down 2.9%
NYSE:TMO opened at $668.89 on Friday. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $727.56. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market cap of $247.84 billion, a PE ratio of 35.28, a P/E/G ratio of 2.82 and a beta of 0.84. The firm's 50 day simple moving average is $678.63 and its 200 day simple moving average is $559.30.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $0.28. The firm had revenue of $12.14 billion during the quarter, compared to analysts' expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The company's revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $5.79 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is currently 9.92%.
Analyst Upgrades and Downgrades
TMO has been the subject of a number of research reports. Guggenheim started coverage on Thermo Fisher Scientific in a research note on Thursday, October 15th. They issued a "buy" rating and a $740.00 price target for the company. Deutsche Bank raised their price objective on Thermo Fisher Scientific from $720.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, October 22nd. Sanford C. Bernstein boosted their price objective on Thermo Fisher Scientific from $520.00 to $575.00 and gave the stock a "market perform" rating in a research report on Friday, July 24th. Royal Bank Of Canada upped their target price on Thermo Fisher Scientific from $580.00 to $730.00 and gave the stock a "sector perform" rating in a report on Thursday, October 22nd. Finally, Stifel Nicolaus increased their target price on Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a "buy" rating in a research report on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $683.64.
View Our Latest Stock Analysis on Thermo Fisher Scientific
Insider Buying and Selling at Thermo Fisher Scientific
In related news, CEO Marc Casper sold 275 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 2,831 shares of the firm's stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total value of $1,999,959.95. Following the transaction, the vice president directly owned 11,560 shares of the company's stock, valued at approximately $8,166,562. This represents a 19.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.